Finch Therapeutics Group Profit Margin

The latest profit margin for FNCH is -497.96% as of June 2024. That compares with -54651.38% in the prior-year period — up 99.1% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Finch Therapeutics Group's historical trend and sector peers before judging valuation or financial health.

Over the past year, FNCH's profit margin moved from -54651.38% to -497.96% — a 99.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Finch Therapeutics Group's valuation or profitability profile.

Against Healthcare companies, FNCH currently prints -497.96% for profit margin, while the sector average sits near 15.58%. That is roughly 3295.3% below the sector mean. Large gaps often invite a closer look at Finch Therapeutics Group's growth, margins, and balance sheet.

Profit Margin shows how effectively Finch Therapeutics Group converts resources into returns. At -497.96%, FNCH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -54651.38% in the prior-year period — up 99.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FNCH's profit margin (-497.96%), review year-over-year change from -54651.38%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.